There is still no vaccine or cure for HIV. However, the disease is no longer an imminent death sentence thanks to the major advances in HIV research and medicine development over recent years.
A great deal of emphasis is placed on antiretroviral treatments. These medicines are specifically designed to block the action of retroviruses, a type of virus, of which HIV is the most well-known.
However, viral resistance to existing drugs continues to be one of the biggest challenges in effectively treating HIV. Consequently the emphasis is currently on expanding the number of antiretroviral drugs available with different modes of action or improved efficacy, tolerability and ease of use.
We know that HIV/AIDS may affect all members of society - that's why we have set up a £10 million seed funding to support a Public Private Partnership into research and development of new HIV/AIDS medicines for children.
Discover more about our commitment to new medicines.
Learn about our current pipeline.
Clinical trials
Like all innovative pharmaceutical companies, we are investing in a series of clinical trials programmes to test each investigational compound’s potential to become a new medicine.
In 2004, GSK established its Clinical Trial Register (renamed Clinical Study Register) to publish clinical trial data related to marketed medicines. Although locally-approved prescribing information will continue to guide appropriate use of medicines, the register serves as another resource for researchers, medical professionals and the public.
Visit the GSK Clinical Study Register
Clinical study data for former Pfizer products can be found here: